论文部分内容阅读
目的通过观察血清CA15-3含量在手术前后的动态变化,并联合血清CYFRA2-11、CEA,以指导临床上对肺癌复发和转移的分析,选择合理的治疗方案。方法采用化学发光法检测血清CA15-3及CEA的含量,采用酶联免疫吸附法检测血清CYFRA2-11的含量。结果在行根治性切除术后,CA15-3和CYFRA2-11水平逐渐降低,术后12d左右降至正常水平,而CEA在术后30d降至正常水平;在行姑息性切除患者,术后CA15-3、CYFRA2-11及CEA水平均不能降至正常水平;如术后有肺癌复发或转移者,术后CA15-3、CYFRA2-11水平再度升高,尤以CA15-3明显,但未发现CEA再次升高。结论手术前后动态检测血清CA15-3和CYFRA2-11的变化规律,有助于判断疗效,检测预后和指导非小细胞肺癌患者术后的综合治疗。
Objective To observe the dynamic changes of serum CA15-3 levels before and after surgery and combine with serum CYFRA2-11 and CEA to guide the clinical analysis of lung cancer recurrence and metastasis, and choose a reasonable treatment plan. Methods The levels of serum CA15-3 and CEA were detected by chemiluminescence method. The serum CYFRA2-11 content was detected by enzyme-linked immunosorbent assay. Results After radical resection, the levels of CA15-3 and CYFRA2-11 gradually decreased, and the levels of CA15-3 and CYFRA2-11 decreased to normal level around 12 d after operation. CEA decreased to normal level at 30 d after operation. In patients undergoing palliative resection, CA15 was postoperative. -3, CYFRA2-11 and CEA levels can not be reduced to normal levels; such as postoperative lung cancer recurrence or metastasis, after the CA15-3, CYFRA2-11 levels increased again, especially in the CA15-3 obvious, but did not find CEA rises again. Conclusion The dynamic changes of serum CA15-3 and CYFRA2-11 levels before and after the operation are helpful to judge the curative effect, detect the prognosis and guide the postoperative comprehensive treatment of NSCLC patients.